“…It has been recommended that 20–30 animals be included in each group, and that the presence or absence of inflammation is clear, based on clinical signs, other laboratory testing, or postmortem findings 10 . Evaluation of overlap performance is commonly performed in nondomesticated mammal APR studies, as noted in Tables 1‐4 13,14,16,22,23,32–37,39,40,42–46,50 . We recommend that to optimize this stage, clinical pathologists work closely with clinicians to gather information about the nature of the putative inflammatory disease and sample handling, such as sample type, storage conditions, number of freeze‐thaw cycles, diagnosis, chronicity of disease, a sample taken before or during treatment, availability of repeated samples from one animal.…”